Literature DB >> 8517709

Influence of therapeutic plasmapheresis on elimination of ceftiaxone.

J S Bakken1, S J Cavalieri, D Gangeness, T Kubat, J R Pollack.   

Abstract

To study the plasma elimination rate of ceftriaxone given to patients undergoing plasmapheresis, a single 2-g intravenous dose of ceftriaxone was given to 11 patients who underwent plasmapheresis 3 h (early group) or 15 h (late group) later. Even though the early patient group had twofold more ceftriaxone removed than the late group, all individual patients had 24-h ceftriaxone levels of 9 micrograms/ml or higher. We conclude that patients undergoing plasmapheresis lasting 150 min or less may safely be treated with 2 g of ceftriaxone once daily without risking periods of subtherapeutic plasma ceftriaxone levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517709      PMCID: PMC187925          DOI: 10.1128/AAC.37.5.1171

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Successful therapy of meningococcal sepsis in acute disseminated lupus erythematosus with plasmapheresis, immunosuppression, and antibiotics.

Authors:  G J Dobos; S Meske; E Keller; W Riegel; P Vaith; H H Peter; P Schollmeyer
Journal:  Klin Wochenschr       Date:  1990-10-03

2.  Influence of plasma exchange pheresis on plasma elimination of ceftriaxone.

Authors:  J S Bakken; S J Cavalieri; D Gangeness
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.

Authors:  G M McKhann; J W Griffin; D R Cornblath; E D Mellits; R S Fisher; S A Quaskey
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

4.  The postantibiotic effect.

Authors:  W A Craig; B Vogelman
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

5.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  Kinetics of ceftazidime during plasmapheresis.

Authors:  F Bozkurt; P Schollmeyer; E Keller
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 7.  Purpura fulminans and symmetrical peripheral gangrene caused by Capnocytophaga canimorsus (formerly DF-2) septicemia--a complication of dog bite.

Authors:  B J Kullberg; R G Westendorp; J W van 't Wout; A E Meinders
Journal:  Medicine (Baltimore)       Date:  1991-09       Impact factor: 1.889

8.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  9 in total
  3 in total

Review 1.  Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.

Authors:  Sherif Hanafy Mahmoud; Jessica Buhler; Eric Chu; Suzie A Chen; Theresa Human
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210

2.  Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients.

Authors:  F Fauvelle; O Lortholary; M Tod; L Guillevin; M Louchahi; A Léon; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 3.  Is Antimicrobial Treatment Effective During Therapeutic Plasma Exchange? Investigating the Role of Possible Interactions.

Authors:  Łukasz J Krzych; Marcelina Czok; Zbigniew Putowski
Journal:  Pharmaceutics       Date:  2020-04-25       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.